Multiple Postdoc Positions in Immunology, Immune Engineering, Biomaterials Engineering, and Cancer Technologies

The “Immunotherapy and Cell Engineering Laboratory” at Georgia Institute of Technology (Georgia Tech)  invites applications for multiple postdoc positions in Immunology, Immune Cell Engineering, Biomaterials Engineering, and Cancer Technologies. We are considering applicants from a wide range of immunology and bioengineering areas, including but not limited to basic and clinical immunology, biomaterials, cell and tissue engineering, microfluidics, cell signaling, cancer biology, microbiome, and epigenetics. Interested candidates should have a Ph.D. in bio- or biomedical engineering or a biomedical science (e.g., biochemistry, immunology, genetics).  Postdoctoral fellows will be compensated at or above NIH guidelines. Georgia Tech offers a comprehensive benefits package designed to meet the diverse needs of our employees ( Interested candidates, email your CV and cover letter to Prof. Ankur Singh at Postdocs will have the opportunity to work closely with collaborators at Georgia Tech, Emory Medicine and Emory Immunology, and continuing collaborations with Cornell University and Weill Cornell Medicine in New York City.

Singh lab research effort centers on creating functional “living” immune tissues as organoids or on-chip to recapitulate selective aspects of lymph nodes. The engineered tissues communicate dynamically with immune cells. We are further interested in understanding how disruption of normal immune processes results in the transformation of “protector” immune cells to immune neoplasms. Research in Singh laboratory is supported by the National Institute of Health (The National Institute of Allergy and Infectious Diseases; National Cancer Institute), Department of Defense, National Science Foundation, 3M, Leukemia and Lymphoma Society, NCI Prostate Cancer SPORE, and industry-supported projects. Our work is published in Nature Methods, Nature Materials, Nature Communications, Nature Reviews Materials, Science Advances, PNAS, Cell Reports, Blood, Science Translational Medicine, Nature Protocols, Advanced Materials, Biomaterials, Molecular Therapy, and J Controlled Release.

We have four major directions:

  • Immuno-engineering: Develop ex vivo immune tissues or lymphatic-on-chip by integrating immune cells, biomaterials, cell adhesion and cell-matrix interactions, tissue mechanics, transport, signaling, and epigenetics. Application in immunity, cancer, infections, and inflammation.
  • Cancer Bioengineering: Develop ex vivo “malignant” immune tissues by integrating lymphoma cells, biomaterials, tissue mechanics, transport and signaling. Specific focus areas include B cell receptor signaling, translational therapeutics, and epigenetics.
  • Immunomodulation in Metabolic Syndrome and Gut Microbiome: Study the effect of metabolic syndrome on a bioengineered system and develop new immunomodulatory biomaterials
  • Immunology: Study mechanisms through which the signaling and epigenome programs the normal and disease-specific immune responses.

The “Immunotherapy and Cell Engineering Laboratory” is located in the Parker H. Petit Institute for Bioengineering & Bioscience (IBB), a hub for interdisciplinary research. The Petit Institute serves as the hub of several core facilities, which are available to affiliated labs at a highly subsidized rate. Details could be found here.

Georgia Tech is an Affirmative Action/Equal Opportunity Employer.

*Singh lab is moving to Georgia Tech from Cornell University.